SINOVAC-BIOTECH
14.7.2022 11:12:07 CEST | Business Wire | Press release
Sinovac Biotech Ltd. (“SINOVAC” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that its COVID-19 vaccine (CoronaVac) has been approved by the Brazilian Health Regulatory Agency (Anvisa) for emergency use in children from 3 to 5 years old on 13 July. These children will receive the same dose that is already applied to minors aged 6 to 17 years and adults and there is no restriction on the application for immunosuppressed children aged 3 to 5 years.
This authorization was given under comprehensive evaluations based on analysis results from all available data on the vaccine and its use in children. Analysis relied on information submitted by the Butantan Institute, with research data from Chile, where the vaccine is already used in this age group, research results on Covid-19 vaccination in Brazil, opinions from invited medical societies, real-life evidence, and published scientific literature data.
Participants in this evaluation activity were the Brazilian Society of Pediatrics (SBP), the Brazilian Society of Infectious Diseases (SBI), the Brazilian Society of Pneumology and Phthisiology (SBPT), the Brazilian Society of Immunizations (SBIm), and the Brazilian Association of Collective Health (Abrasco). To assist Anvisa in evaluating the vaccine, the experts from the above institutions had access to technical materials and research data on the vaccine.
CoronaVac has been authorized for emergency use for adults in Brazil since January 17, 2021. Following, the Anvisa authorized the extension of the use of the vaccine to children and adolescents 6 to 17 years of age on January 20, 2022.
As of July 14, 2022, CoronaVac is authorized for Emergency Use for minors in 14 countries and regions, including Chile, Colombia, Ecuador, Brazil, and the countries and regions in Asia and Africa.
About SIONVAC
Sinovac Biotech Ltd., (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases.
SINOVAC’s product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A and B, seasonal influenza, pneumococcal disease, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), varicella, mumps, and poliomyelitis.
The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The Healive®, hepatitis A vaccine, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine commercialized in China in 2016. In 2022, SINOVAC’s Sabin-strain inactivated polio vaccine (sIPV) was prequalified by the WHO.
SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program.
SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations.
For more information, please see the Company’s website at www.sinovac.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220714005372/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Murata Collaborates with Synopsys to Provide Simulation Models Through Ansys Electromagnetic and Thermal Analysis Tools16.6.2026 04:00:00 CEST | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) announces a new collaboration with Synopsys, Inc., enabling users of Synopsys' simulation tools to navigate directly to Murata's website to access and download the latest high-performance simulation models from Murata. The collaboration covers Synopsys' 3D electromagnetic field analysis tool Ansys HFSS™ and thermal analysis tool Ansys Icepak®, and marks a significant step toward streamlining the simulation workflow for electronic circuit designers. Murata is also the first company to offer passive component simulation models via Ansys Icepak*. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615241645/en/ [Murata Manufacturing Co., Ltd.] New collaboration with Synopsys As demand for high-speed, high-capacity communications continues to grow, electronic circuit design has become increasingly complex. Engineers must now account for a range of physical phenomena
Trimontium Launches with $1.5 billion in AUM, Redefining Flexible CapitalSolutions16.6.2026 01:01:00 CEST | Press release
Founded by former Blackstone executive Vlado Spasov, Trimontium is an institutionally backed alternative asset manager purpose-built to deliver flexible capital solutions across Europe and North America Trimontium (the “Firm”), an institutionally backed alternative asset manager specialising in flexible capital solutions, today announced its launch with $1.5 billion in assets under management. The Firm’s investment approach is rooted in credit and special-situations expertise, with the flexibility to originate and execute tailored financing solutions across the full capital structure for a wide range of corporate needs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615892895/en/ Trimontium Founder and CIO, Vlado Spasov Founded by former Blackstone executive Vlado Spasov, Trimontium is one of the largest first-time alternative asset managers based in Europe focused on flexible capital solutions to launch, according to ava
Newmont Announces Key Executive Appointments for the Next Phase of Delivery15.6.2026 23:20:00 CEST | Press release
Newmont Corporation (NYSE: NEM, ASX: NEM, PNGX: NEM) (“Newmont”) today announced leadership appointments that further shape its go-forward Executive Leadership Team under President and Chief Executive Officer Natascha Viljoen and reflect the depth of leadership talent within the company. Effective July 1, 2026, Brian Tabolt has been appointed Chief Financial Officer, Mark Rodgers has been appointed Chief Operating Officer, and David Thornton has been appointed Chief Technical Officer. In addition, David Fry has been promoted to Executive Vice President, Project Development, reflecting the importance of disciplined project development and execution as Newmont advances its highest-return growth opportunities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615487768/en/ Mark Rodgers - COO “These appointments bring together respected leaders with deep industry experience and a strong understanding of our operational, financia
Westlake Expands Global Chlorovinyls Manufacturing Capacity With Acquisition of PVC and VCM Plants in Wilhelmshaven, Germany15.6.2026 20:18:00 CEST | Press release
Westlake Corporation (NYSE: WLK) (“Westlake”) announced today that its German subsidiary, Westlake Vinnolit GmbH & Co. KG, has completed the previously-announced acquisition of a polyvinyl chloride and vinyl chloride monomer production site located in Wilhelmshaven, Germany (the “Wilhelmshaven plant”). The Wilhelmshaven plant, which was previously in insolvency administration, has the capacity to produce 380,000 metric tons of PVC per year. “This acquisition strengthens our Performance & Essential Materials business by expanding our global chlorovinyls manufacturing footprint and complements our existing chlorovinyl production facilities in Europe and North America,” said Jean-Marc Gilson, President and Chief Executive Officer of Westlake. “The Wilhelmshaven plant, which is located in Lower Saxony on Germany’s North Sea coast, benefits from advantageous logistical infrastructure, including a deep-water dock that enables efficient raw-materials supply. We look forward to welcoming the s
Onera Announces Integration of the Onera hPSG® Solution With Somnoware15.6.2026 19:35:00 CEST | Press release
Onera hPSG®, an end-to-end home polysomnography solution from Onera Health, is now integrated into Somnoware, enabling their customers to conduct Polysomnography tests (PSGs) in the patient's home while managing the entire workflow in Somnoware. Onera Health, a leader in transforming sleep medicine, announces that its end-to-end home polysomnography solution, the Onera hPSG® solution, now integrates with Somnoware by ResMed sleep lab management software. This integration enables clinicians to conduct Polysomnography tests (PSGs) where patients sleep most comfortably, in their own home, while managing the entire workflow in Somnoware. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615106079/en/ Onera hPSG®, an end-to-end home polysomnography solution from Onera Health, is now integrated into Somnoware, enabling their shared customers to conduct Polysomnography tests (PSGs) in the patient's home while managing the entire wo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom